SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: SHR-A1811; Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials